[go: up one dir, main page]

WO2024173352A3 - Méthodes de traitement du cancer avec une protéine chimérique à base de sirp1a - Google Patents

Méthodes de traitement du cancer avec une protéine chimérique à base de sirp1a Download PDF

Info

Publication number
WO2024173352A3
WO2024173352A3 PCT/US2024/015542 US2024015542W WO2024173352A3 WO 2024173352 A3 WO2024173352 A3 WO 2024173352A3 US 2024015542 W US2024015542 W US 2024015542W WO 2024173352 A3 WO2024173352 A3 WO 2024173352A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
sirp1a
treating cancer
chimeric protein
based chimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/015542
Other languages
English (en)
Other versions
WO2024173352A2 (fr
Inventor
Arundathy PANDITE
Fatima RANGWALA
Thomas LAMPKIN
Taylor Schreiber
George FROMM
Suresh DE SILVA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shattuck Labs Inc
Original Assignee
Shattuck Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shattuck Labs Inc filed Critical Shattuck Labs Inc
Publication of WO2024173352A2 publication Critical patent/WO2024173352A2/fr
Publication of WO2024173352A3 publication Critical patent/WO2024173352A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne, en partie, des compositions et des procédés, y compris des protéines chimériques, qui trouvent une utilisation dans le traitement d'une maladie, telle que des immunothérapies pour le cancer.
PCT/US2024/015542 2023-02-13 2024-02-13 Méthodes de traitement du cancer avec une protéine chimérique à base de sirp1a Ceased WO2024173352A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202363484727P 2023-02-13 2023-02-13
US63/484,727 2023-02-13
US202363502039P 2023-05-12 2023-05-12
US63/502,039 2023-05-12

Publications (2)

Publication Number Publication Date
WO2024173352A2 WO2024173352A2 (fr) 2024-08-22
WO2024173352A3 true WO2024173352A3 (fr) 2024-10-24

Family

ID=92420638

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/015542 Ceased WO2024173352A2 (fr) 2023-02-13 2024-02-13 Méthodes de traitement du cancer avec une protéine chimérique à base de sirp1a

Country Status (1)

Country Link
WO (1) WO2024173352A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006125143A2 (fr) * 2005-05-18 2006-11-23 Novartis Ag Methodes de diagnostic et de traitement des maladies proliferatives mediees par la signalisation cd40
WO2022061124A1 (fr) * 2020-09-17 2022-03-24 Shattuck Labs, Inc. Dosage clinique de protéine chimérique sirp1a

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006125143A2 (fr) * 2005-05-18 2006-11-23 Novartis Ag Methodes de diagnostic et de traitement des maladies proliferatives mediees par la signalisation cd40
WO2022061124A1 (fr) * 2020-09-17 2022-03-24 Shattuck Labs, Inc. Dosage clinique de protéine chimérique sirp1a

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CURRAN K.J. ET AL.: "Enhancing Antitumor Efficacy of Chimeric Antigen Receptor T Cells Through Constitutive CD40L Expression", MOL. THER., vol. 23, no. 4, 10 February 2015 (2015-02-10), pages 769 - 778, XP002789068, DOI: 10.1038/mt.2015.4 *

Also Published As

Publication number Publication date
WO2024173352A2 (fr) 2024-08-22

Similar Documents

Publication Publication Date Title
EP4566621A3 (fr) Protéines de liaison à dll3/cd3 pour le traitement du cancer
MX2022011676A (es) Proteinas de fusion de il12 con enmascaramiento y metodos para su uso.
MY190625A (en) Anti-vegf protein compositions and methods for producing the same
WO2010065824A3 (fr) Agents induisant l'apoptose pour le traitement du cancer et de maladies immunes et auto-immunes
UA106079C2 (uk) Індукуючі апоптоз засоби для лікування злоякісної пухлини і імунних і аутоімунних захворювань
MY209387A (en) Multi-specific binding proteins for cancer treatment
WO2022038417A3 (fr) Polypeptides il-18 modifiés et leurs utilisations
WO2002069886A3 (fr) Proteines modifiees, toxines mises au point et procedes de fabrication de celles-ci
WO2022082073A3 (fr) Compositions et méthodes de ciblage de muc18
WO2022167816A3 (fr) Anticorps
WO2015006287A3 (fr) Compositions préparées de volaille et leurs procédés d'utilisation
ZA202110285B (en) Antibodies and methods of use
ZA201907371B (en) Methods and compositions for treating allergic ocular diseases
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
WO2020142740A8 (fr) Traitement de la maladie de sjögren à l'aide de protéines de fusion de type nucléases
EA202092487A1 (ru) Ферменты кинурениназы человека и их применение
WO2021003050A3 (fr) Agent de liaison à cd38 et utilisations associées
MX2024014830A (es) Compuestos de degradacion de wee1 y usos de los mismos
MX2023006777A (es) Composiciones y métodos que comprenden antagonistas de proteína 2 relacionada con frizzled secretada (sfrp2).
WO2019075216A8 (fr) Anticorps se liant à la plectine-1 et utilisations associées
WO2024173352A3 (fr) Méthodes de traitement du cancer avec une protéine chimérique à base de sirp1a
PH12023550213A1 (en) Antigen binding protein
WO2021058711A3 (fr) Protéines de liaison à un antigène
WO2020210480A3 (fr) Vecteurs de facteur h et leurs utilisations
WO2024083925A3 (fr) Nouveaux anticorps anti-napi2b et conjugués anticorps-médicament basés sur ceux-ci, procédés thérapeutiques et utilisations de ceux-ci

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24757527

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE